These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 5700392)

  • 21. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
    Erem C
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estrogens in oral contraceptives: historical perspectives.
    Goldzieher JW
    Johns Hopkins Med J; 1982 May; 150(5):165-9. PubMed ID: 7043034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral contraceptives in the puerperium.
    Sulak PJ
    Int J Fertil; 1991; 36 Suppl 2():87-9. PubMed ID: 1679422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Changes in blood coagulation during hormonal contraception].
    von Hugo R; Lenz A; Hafter R
    Gynakol Rundsch; 1985; 25 Suppl 2():138-41. PubMed ID: 4093018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral contraceptive use and venous thromboembolism: a consideration of the impact of bias and confounding factors on epidemiological studies.
    Rekers H; Norpoth T; Michaels MA
    Eur J Contracept Reprod Health Care; 1996; 1(1):21-30. PubMed ID: 9678134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Estrogen therapy for the climateric and thromboembolic risk].
    Campagnoli C; Prelato L; Rossetti MG
    Minerva Ginecol; 1980 May; 32(5):429-35. PubMed ID: 7393492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EFFECT OF A PROGESTIN-ESTROGEN ORAL CONTRACEPTIVE ON BLOOD CLOTTING FACTORS.
    HOUGIE C; RUTHERFORD RN; BANKS AL; COBURN WA
    Metabolism; 1965 Mar; 14():SUPPL:411-7. PubMed ID: 14261425
    [No Abstract]   [Full Text] [Related]  

  • 28. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
    Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
    Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relationship of clotting factors to dosage levels of estrogen and progestogen-like combinations.
    Banks AL; Rutherford RN; Coburn WA; Welsh RL
    Int J Fertil; 1966; 11(3):277-80. PubMed ID: 5967993
    [No Abstract]   [Full Text] [Related]  

  • 30. [How to choose an oral contraceptive in 1984].
    Rozenbaum H
    Contracept Fertil Sex (Paris); 1984 Nov; 12(11):1201-6. PubMed ID: 12266609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The case for a lower dose pill. Assessing the impact of estrogen dose.
    Brown S; Cropfield O
    ORGYN; 1995; (2):36-9. PubMed ID: 12319251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Potential advantages of triphasic combined oral contraceptives in the light of recent epidemiological and endocrinometabolic data].
    Gaspard U; Dubois M
    Contracept Fertil Sex (Paris); 1982 Sep; 10(9):551-60. PubMed ID: 12311606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cardiovascular effects of oral contraceptives.
    Wood JE
    Mod Concepts Cardiovasc Dis; 1972 Aug; 41(8):37-40. PubMed ID: 4343099
    [No Abstract]   [Full Text] [Related]  

  • 34. [Veins and contraception].
    Reinharez D; Monsonego J
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):131-6. PubMed ID: 12280199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of long-term steroid contraception on coagulation in Asian women.
    Tsakok FH; Ho LM; Koh S; Ratnam SS
    Singapore Med J; 1980 Aug; 21(4):612-9. PubMed ID: 7221571
    [No Abstract]   [Full Text] [Related]  

  • 36. Reducing the risk of oral contraceptive-induced thrombosis.
    Pizzo SV
    Drug Ther (NY); 1981 Sep; 11(9):101-8. PubMed ID: 12263495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral contraceptive risks: a realistic appraisal.
    Bressler R; Durand JL
    Drug Ther (NY); 1979 Oct; 9(10):81-95. PubMed ID: 12279276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An appraisal of certain problems involved in the use of steroid compounds for contraception.
    Hertz R
    Caribb Med J; 1966; 28(1-4):26-35. PubMed ID: 12255250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparison of changes in activity of some hemocoagulation factors during contraception and therapy with combinations of synthetic steroids with varied gestagenic components].
    Misinger I; Hermanská Z
    Cas Lek Cesk; 1971 Feb; 110(9):196-9. PubMed ID: 5547223
    [No Abstract]   [Full Text] [Related]  

  • 40. [Oral contraceptives: pharmacotherapy of normal women (author's transl)].
    Bühler FR
    Schweiz Rundsch Med Prax; 1976 Jan; 65(1):3-5. PubMed ID: 1250821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.